Conferences

Bayer to Present Key Data Across Oncology Portfolio Showcasing Significant Advances in Cancer Care at 2022 ASCO Annual Meeting May 19, 2022

AUA 2022: Surrogate Endpoints as Predictors of Survival in Metastatic Urothelial Cancer Trials May 18, 2022

AUA 2022: Frequency of Fibroblast Growth Factor Receptor Alterations and Association With Bacillus Calmette-Guerin Outcomes in a Real-World Genomic Analysis of High-Risk Non-Muscle-Invasive Bladder Cancer (GARNER) Study May 18, 2022

AUA 2022: Longitudinal Health-Related Quality of Life Outcomes in Adults with Non-Muscle-Invasive Bladder Cancer Receiving a Chemoablative Gel as a Primary Treatment (Optima II: Phase 2b, single arm, open-label trial) May 18, 2022

AUA 2022: A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating BCG Unresponsive Non-Muscle Invasive Bladder Cancer: Recirculant Hyperthermic Intravesical Chemotherapy May 18, 2022

AUA 2022: Neoadjuvant Pembrolizumab May Result in Long-Term Outcome Improvement in Biomarker-Unselected Patients With Muscle-Invasive Bladder Cancer: Updated Results From: Updated results from PURE-01 May 18, 2022

AUA 2022: Prevalence and Predictors of Psychological Distress Among Patients Treated for Bladder Cancer May 18, 2022

AUA 2022: Evaluating Intravesical Nadofaragene Firadenovec and Immune Checkpoint Blockade Combination Therapy in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Evidence From a Phase 3 Trial May 18, 2022

AUA 2022: Immediate Radical Cystectomy vs. BCG Immunotherapy for T1 High Grade Non-Muscle-Invasive Bladder Cancer: an International Multicentre Collaboration May 18, 2022

AUA 2022: CORE1: Phase 2, Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer Unresponsive to BCG May 18, 2022

AUA 2022: A Phase II Study of Check Point Inhibitor, Durvalumab (MEDI4736) for Bacillus Calmette-Guerin Unresponsive Carcinoma in Situ of the Bladder May 18, 2022

AUA 2022: Two-Year Efficacy Follow-Up of a Phase I Trial of Intravesical BCG Combined with Intravenous Pembrolizumab in Recurrent or Persistent High-Grade NMIBC after Previous BCG Treatment May 18, 2022

AUA 2022: Development of Patient-Derived Kidney Cancer Organoid; Application to Drug Screening Models and Its Challenges May 18, 2022

AUA 2022: The Patient Voice: Experiences with Ureteral Stent Removal – A Urinary Stone Disease Research Network (USDRN) Study May 18, 2022

AUA 2022: Determining the Threshold of Safety for Intrarenal Pressure During Flexible Ureteroscopy Using an in Vivo Pig Model May 18, 2022

AUA 2022: Outcomes of Cytoreductive Nephrectomy Followed by Active Surveillance in Metastatic Renal Cell Carcinoma May 18, 2022

AUA 2022: 68 Ga-PSMA PET/CT for Preoperative Lymph Node Staging of High Risk Prostate Cancer May 18, 2022

AUA 2022: Can Pelvic Lymph Node Dissection Be Omitted at the Time of Radical Prostatectomy in Patients With a Negative Preoperative 68Ga-PSMA PET/CT? The Importance of Patient Risk Stratification According to Individual Risk of Lymph Node Metastases May 18, 2022

AUA 2022: Final Results of a Phase I Trial of WST11 (TOOKAD Soluble) Vascular-Targeted Photodynamic Therapy for Upper Tract Urothelial Carcinoma May 18, 2022

AUA 2022: Impact of Node Count on Survival Outcomes of Lymph Node Dissection in non-Metastatic Upper Tract Urothelial Carcinoma: Analysis of the ROBUUST Registry May 17, 2022

Page 1 of 465

email news signup